Integral Investment Advisors Inc. Buys 266 Shares of Johnson & Johnson $JNJ

Integral Investment Advisors Inc. lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.6% in the second quarter, HoldingsChannel reports. The fund owned 16,908 shares of the company’s stock after acquiring an additional 266 shares during the period. Johnson & Johnson makes up approximately 0.7% of Integral Investment Advisors Inc.’s holdings, making the stock its 28th largest holding. Integral Investment Advisors Inc.’s holdings in Johnson & Johnson were worth $2,583,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Nuveen LLC purchased a new stake in shares of Johnson & Johnson in the first quarter worth $1,369,188,000. Bank of New York Mellon Corp increased its stake in Johnson & Johnson by 26.4% in the 1st quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company’s stock worth $3,844,580,000 after buying an additional 4,842,582 shares in the last quarter. Pacer Advisors Inc. raised its holdings in Johnson & Johnson by 1,382.0% during the first quarter. Pacer Advisors Inc. now owns 3,030,084 shares of the company’s stock valued at $502,509,000 after acquiring an additional 2,825,626 shares during the period. Assenagon Asset Management S.A. boosted its stake in shares of Johnson & Johnson by 159.6% in the second quarter. Assenagon Asset Management S.A. now owns 4,159,260 shares of the company’s stock worth $635,327,000 after acquiring an additional 2,557,388 shares during the period. Finally, Kingstone Capital Partners Texas LLC purchased a new stake in shares of Johnson & Johnson during the second quarter worth about $401,420,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently commented on JNJ. Loop Capital set a $190.00 price target on Johnson & Johnson in a research note on Wednesday, October 22nd. Barclays boosted their price target on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 17th. Daiwa Capital Markets upgraded Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 price objective for the company in a research report on Monday, October 20th. Sanford C. Bernstein boosted their target price on Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a research report on Monday, October 6th. Finally, Guggenheim raised Johnson & Johnson from a “neutral” rating to a “buy” rating and increased their price target for the company from $167.00 to $206.00 in a research note on Tuesday, September 23rd. Three analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus target price of $199.05.

Insider Buying and Selling

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $190.31 on Tuesday. The firm has a market capitalization of $458.50 billion, a price-to-earnings ratio of 18.37, a PEG ratio of 2.24 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. The business has a 50 day simple moving average of $182.54 and a 200-day simple moving average of $166.65. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $194.48.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The company had revenue of $24.02 billion for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. Equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be paid a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. Johnson & Johnson’s payout ratio is currently 50.19%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.